Anti-hepatitis C virus therapy in chronic kidney disease patients improves long-term renal and patient survivals

Table 1 Baseline characteristics of the three study cohorts, 1997-2012, n = 6266

Variables	Propensity score-matched CKD patients
	Treated(n = 482)	Untreated(n = 1928)	Uninfected(n = 3856)	P1 value
Sex				0.38
Men	253 (52.5)	979 (50.8)	2032 (52.7)
Women	229 (47.5)	949 (49.2)	1824 (47.3)
Age in yr	58.5 ± 10.5	58.5 ± 13.7	58.4 ± 14.1	0.96
Interferon-based therapy duration in yr	0.5 ± 0.8	-	-
Comorbidity
Diabetes	228 (47.3)	878 (45.5)	1727 (44.8)	0.55
Hypertension	290 (60.2)	1150 (59.6)	2315 (60.0)	0.95
Coronary heart disease	182 (37.8)	746 (38.7)	1519 (39.4)	0.73
Hyperlipidemia	239 (49.6)	961 (49.8)	1938 (50.3)	0.93
Cirrhosis	120 (24.9)	446 (23.1)	892 (23.1)	0.68
ACEI/ARB use	14 (2.9)	37 (1.9)	66 (1.7)	0.19
Enrollee category				< 0.0001
1	152 (31.5)	546 (28.3)	1332 (34.5)
2	10 (2.1)	30 (1.6)	61 (1.6)
3	255 (52.9)	968 (50.2)	1622 (42.1)
4	65 (13.5)	384 (19.9)	841 (21.8)
Number of medical visits	38.6 ± 25.6	34.4 ± 26.7	30.0 ± 25.0	< 0.0001
Charlson comorbidity index score	4.2 ± 2.7	3.5 ± 2.6	3.2 ± 2.7	< 0.0001

Data are presented as n (%).

¹For comparison among three cohorts. Categorical variables given as number (percentage); continuous variable, as mean ± SD. CKD: Chronic kidney disease; ACEI/ARB: Angiotensin converting enzyme inhibitor/angiotensin receptor blocker.